Nasdaq · Biological Products, (No Diagnostic Substances)
18 entities across 4 jurisdictions. Read directly from the company’s own 10-K EX-21 filed 2026-02-25 — see the exhibit.
| Entity | Jurisdiction | Note |
|---|---|---|
| Exscientia Limited | United Kingdom | |
| Exscientia (UK) Holdings Ltd. | United Kingdom | |
| Exscientia AI Ltd. | Scotland | |
| Kinetic Discovery Ltd | Scotland | |
| Exscientia Inc. | Delaware | |
| Exscientia Ventures I Inc. | Delaware | |
| RE Ventures I LLC | Delaware | |
| Exscientia Ventures II Inc. | Delaware | |
| RE Ventures II LLC | Delaware | |
| Recursion London Ltd. | United Kingdom | |
| Recursion Canada, Inc. | Canada | |
| Valence Discovery Inc. | Canada | |
| Valence Discovery USA, Inc. | Delaware | |
| Cyclica Therapeutics Inc. | Canada | |
| Cyclica Inc. | Delaware | |
| Giro Health Inc. | Delaware | |
| B.C. Unlimited Liability Company | Canada | |
| CereXis, Inc. | Delaware |
Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
Bankruptcy-risk screen combining working capital, retained earnings, operating income, market value against liabilities, and asset turnover. Above 2.99 is the safe zone; below 1.81 is distress.
| Year | Revenue | Net income | Free cash flow | Gross margin | Shares |
|---|---|---|---|---|---|
| FY2020 | $4.0M | −$87.0M | −$51.2M | — | 21,781,386 |
| FY2021 | $10.2M | −$186.5M | −$198.4M | — | 125,348,110 |
| FY2022 | $39.8M | −$239.5M | −$120.6M | — | 175,537,487 |
| FY2023 | $44.6M | −$328.1M | −$299.7M | — | 207,853,702 |
| FY2024 | $58.8M | −$463.7M | −$372.9M | — | 274,207,146 |
| FY2025 | $74.7M | −$644.8M | −$378.3M | — | 447,446,109 |
2 institutions tracked — 1 added, 1 reduced. Index money added 1,544,051 shares while active managers cut 187,500.
| Manager | Kind | Shares | Change | Value |
|---|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | Index | 13,819,135 | +1,544,051 | $50.7M |
| BAILLIE GIFFORD & CO | Value | 23,487,907 | −187,500 | $86.2M |
From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register.
Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.
RECURSION PHARMACEUTICALS, INC. files under SIC 2836 — all 11 biological products, (no diagnostic substances) companies compared on assets and F-score.
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.
